Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Open accessThe DOI matches its Crossref record; 555 of the 555 references it cites were found in a registry or an index; 131 of the 460 sources its claims cite were checked for support.
Abstract
In the context of global ageing, the prevalence of neurodegenerative diseases and dementia, such as Alzheimer’s disease (AD), is increasing. However, the current symptomatic and disease-modifying therapies have achieved limited benefits for neurodegenerative diseases in clinical settings. Halting the progress of neurodegeneration and cognitive decline or even improving impaired cognition and function are the clinically meaningful goals of treatments for neurodegenerative diseases. Ageing is the primary risk factor for neurodegenerative diseases and their associated comorbidities, such as vascular pathologies, in elderly individuals. Thus, we aim to elucidate the role of ageing in neurodegenerative diseases from the perspective of a complex system, in which the brain is the core and peripheral organs and tissues form a holistic network to support brain functions. During ageing, the progressive deterioration of the structure and function of the entire body hampers its active and adaptive responses to various stimuli, thereby rendering individuals more vulnerable to neurodegenerative diseases. Consequently, we propose that the prevention and treatment of neurodegenerative diseases should be grounded in holistic antiageing and rejuvenation means complemented by interventions targeting disease-specific pathogenic events. This integrated approach is a promising strategy to effectively prevent, pause or slow down the progression of neurodegenerative diseases.
Overview
CoChat Summary
TL;DR
This review argues that because ageing is the primary risk factor for neurodegenerative diseases, treatment should be grounded in holistic antiageing and rejuvenation strategies across molecular, cellular, systemic and individual levels, complemented by interventions targeting disease-specific pathogenic events. It synthesizes preclinical and clinical evidence for such an integrated approach to preventing, pausing or slowing neurodegeneration.
Key findings
- Ageing is presented as an "accelerator" of neurodegeneration: AD prevalence rises from 5% at ages 65–74 to 13.1% at 75–84 and 33.2% at 85+ (US, 2022); PD prevalence rises from 41 per 100,000 at ages 40–49 to 1,903 per 100,000 at 80+; ALS prevalence is 0.2 per 100,000 at ages 18–39 versus 17.2 per 100,000 at 70–79.
- Comorbidities are the rule rather than the exception: in the ROS/MAP cohort, ~97% of persons with probable AD had other neurodegenerative or vascular comorbidities, and >86% of cognitively unimpaired older persons had vascular, AD or other degenerative comorbidities.
- The authors propose a complex adaptive systems (CAS) framework in which neurodegeneration arises from emergent homeostatic imbalance across molecular, cellular, organ and organismal scales, rather than from a single molecule or cell.
- Antiageing interventions are catalogued across levels: molecular (e.g., GDF11, klotho, metformin lowering epigenetic age by up to 6.1 years in the frontal lobe of monkeys; rapamycin/acarbose/phenylbutyrate cocktails), cellular (senolytics extending lifespan up to 35% in pre-ageing mice; young plasma extracellular vesicles increasing median lifespan 12.4%), systemic (young blood, bone marrow transplantation increasing maximum lifespan 30%, FMT, anti-inflammation such as IL-11 neutralization extending average mouse lifespan 24.9%), and individual (caloric restriction, exercise, sleep/diet; a multimodal diet-exercise-sleep intervention reversed epigenetic age by 3.2 years).
- Clinical trials reviewed include effective results for allopregnanolone, isoflavones, benfotiamine, fish oil/lipoic acid, and plasma exchange, while intranasal insulin, naproxen/celecoxib and nilotinib were ineffective; senolytics showed phase 1 safety in AD.
Methods
- Narrative review (no systematic search or meta-analytic protocol described) synthesizing epidemiological, mechanistic, preclinical and clinical literature on ageing and neurodegenerative diseases (AD, PD, ALS, FTLD, HD).
- Evidence drawn from population/epidemiological datasets (WHO, CDC, ROS/MAP, UK Biobank, CALERIE, REACT), animal and cell models, and a tabulated set of clinical trials (Table 2) with identifiers, phases and reported results.
- Organizes evidence by mechanistic level (molecular, cellular, tissue/organ, circuit, functional), by body–brain axes (heart, liver, gut, kidney, lung, muscle, bone, blood, immune, endocrine), and by intervention level (molecular, cellular, systemic, individual).
Limitations
- Stated by the paper: most studies are conducted in artificially induced animal models (e.g., APP/PS1 mice) that do not reflect sporadic disease, since familial AD accounts for less than 5% of cases; such models may underestimate peripheral and brain ageing contributions.
- Stated by the paper: mouse, Drosophila and nematode lifespans are inadequate for modelling gradual human ageing, so antiageing therapies should be validated in longer-lived species (non-human primates, naked mole rats).
- Stated by the paper: the magnitude and duration of antiageing effects require long-term follow-up; individual heterogeneity (age, personality, comorbidities, lifestyle, education) is poorly understood; and side effects/adverse reactions are often downplayed.
- Evident from the text: as a narrative review without a systematic search strategy, selection of cited evidence may be subject to the authors' framing, and several cited clinical trials are ongoing with results not yet reported (blank entries in Table 2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
89 Valid · 5 Not valid · 242 Not checked · 87 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Subsequent clinical trials have indicated that cognitive and behavioural improvements could be achieved through fecal microbiota transplantation (FMT) in patients with mild cognitive impairment as well as those suffering from PD.76,77”
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Milestone events of studies on antiageing strategies
What the sources say
- Partly supportedcites [76] Chen, X. et al. Preliminary evidence for developing safe and efficient fecal microbiota transplantation as potential treatment for aged related cognitive impairments. Front. Cell Infect. Microbiol. 13, 1103189 (2023). sourceExperimental — accuracy not yet measured
The Results section reports that, after FMT, cognitive scores in two patients with mild cognitive impairment improved slightly or were maintained, while daily-living scores improved. The paper does not report an FMT trial in patients with Parkinson’s disease or a distinct behavioural-improvement outcome. (LLM, conf=0.88)
- Partly supportedcites [77] Huang, H. et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation: A case report. Medicine 98, e16163 (2019). sourceExperimental — accuracy not yet measured
The Case presentation (page unavailable) reports reduced tremor and improved constipation after FMT in one patient with Parkinson’s disease. It does not report cognitive or behavioural improvements, study patients with mild cognitive impairment, or describe a clinical trial; the Discussion calls it a first attempt to treat PD with FMT. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two recent clinical trials involving young plasma infusion in patients with AD and PD, respectively, have further validated this intervention strategy for neurodegenerative diseases.73,74”
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Milestone events of studies on antiageing strategies
What the sources say
- Partly supportedcites [73] Sha, S. J. et al. Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial. JAMA Neurol. 76, 35–40 (2019). sourceExperimental — accuracy not yet measured
The Key Points identify a clinical trial of young-plasma infusions in patients with mild to moderate AD and report that the infusions were tolerated. The Discussion says the trial established safety and feasibility, but that efficacy could not be determined; it therefore does not validate young plasma as an effective intervention for AD. The separate PD trial is not assessed under this citation. (LLM, conf=0.88)
- Partly supportedcites [74] Parker, J. E. et al. Safety of Plasma Infusions in Parkinson’s Disease. Mov. Disord. 35, 1905–1913 (2020). sourceExperimental — accuracy not yet measured
The paper's Conclusions report that young plasma infusion was safe and feasible in people with PD, with preliminary signs of improvement. But the Discussion describes the study as an uncontrolled phase I trial and cautions that its improvement finding is preliminary; it does not validate young plasma as an effective treatment for PD or neurodegenerative diseases more broadly. This verdict addresses the PD trial attributed to this source, not the separately cited AD trial. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In 2009, rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR) pathway, was shown to significantly extend the lifespan of mammals.58”
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Milestone events of studies on antiageing strategies
What the sources say
- Supportedcites [58] Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009). source
The Abstract reports that rapamycin, an mTOR-pathway inhibitor, extended median and maximal lifespan in male and female mice. It also reports statistically significant survival benefits compared with controls (p < 0.0001). The mammalian evidence in this paper is specifically from mice. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The expression of aquaporin-4 (AQP4) in astrocytes significantly influences the transport and clearance functions of the glymphatic system.155”
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Systemic regulatory mechanisms of ageing in neurodegenerative diseases > Molecular and cellular networks of ageing in neurodegenerative diseases
What the sources say
- Supportedcites [155] Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4, 147ra111 (2012). source
The DISCUSSION of our copy proposes the name 'glymphatic' for this para-arterial CSF influx / paravenous ISF clearance pathway and states that 'Interstitial bulk flow between these influx and efflux pathways depends upon trans-astrocytic water movement.' The RESULTS ('Astroglial water transport supports CSF flux into the parenchyma'; 'Astroglial water transport facilitates bulk ISF solute clearance from the parenchyma') show that in Aqp4-null mice TR-d3 movement from the paravascular space into the interstitium was effectively abolished and [3H]mannitol clearance was reduced by ~70%, with Aβ1-40 clearance reduced by ~55% (RESULTS, 'AQP4 facilitates the para-vascular clearance of interstitial amyloid β'). The paper also links the degree/polarization of AQP4 expression in periarterial versus perivenous astroglial endfeet to directional bulk flow (RESULTS; DISCUSSION, 'Role of AQP4 in paravascular pathway function'), covering both the transport and clearance limbs of the claim. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The expression and functionality of proteins that form tight junctions between endothelial cells, such as occludin and claudin, are reduced.151,152”
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Systemic regulatory mechanisms of ageing in neurodegenerative diseases > Molecular and cellular networks of ageing in neurodegenerative diseases
What the sources say
- Partly supportedcites [151] Geng, J. et al. Blood-Brain Barrier Disruption Induced Cognitive Impairment Is Associated With Increase of Inflammatory Cytokine. Front. Aging Neurosci. 10, 129 (2018). sourceExperimental — accuracy not yet measured
The Results section reports reduced occludin and claudin-5 expression and disrupted tight-junction staining in 8-week diabetic rats compared with normal rats. The Discussion links these changes to impaired blood–brain barrier function. The paper does not establish that these changes occur with ageing; the eight weeks describe time after diabetes induction, not the rats’ age. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [152] Bony, B. A. et al. Claudin-1-Targeted Nanoparticles for Delivery to Aging-Induced Alterations in the Blood-Brain Barrier. ACS Nano 15, 18520–18531 (2021). sourceExperimental — accuracy not yet measured
The introductory passage says claudin-5 expression decreases during aging and links altered tight-junction protein expression to BBB leakiness. But the Conclusions report increased claudin-1 expression in aging brain endothelial cells, while Results and Discussion found no difference in total claudin-1 or claudin-5 protein levels between the mouse age groups studied. The supplied passages do not establish that occludin expression or tight-junction protein functionality generally decreases with age. Page numbers were not provided. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
177 more claims · 37 with their cited sources checked
Create a free account to see all 423 claims and to verify the 329 references still open.
- It may state two separate claims as one. 214
- Probably not a substantial claim. 45
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Increasingly, AD is being reframed as a systemic disorder linked to global aging processes rather than a purely localized brain disease [4,5].”
From Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease (2025) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Antiageing strategies for neurodegenerative diseases: clinical trials > Neuroprotection
“Drugs such as PYC857 are being studied for their antioxidant and anti-inflammatory effects on treating ALS.”
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Antiageing strategies for neurodegenerative diseases: clinical trials
“| Anti-inflammation | PTC857 | NCT05349721 | ALS | Phase 2 | | |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > Systemic regulatory mechanisms of ageing in neurodegenerative diseases > Body‒brain axes in relation to ageing and neurodegenerative diseases
“Studies in humans have revealed that liver function decreases with age, as indicated by increased serum γ-glutamyl transpeptidase and alanine aminotransferase levels.219”
§ Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances > References
“219. Dong, M. H., Bettencourt, R., Barrett-Connor, E. & Loomba, R. Alanine aminotransferase decreases with age: the Rancho Bernardo Study.”
Citations
Cites
1 retracted
RETRACTED: New intranasal and injectable gene therapy for healthy life extension
Jaijyan, D. K., Selariu, A., Cruz-Cosme, R., Tong, M., Yang, S., Stefa, A., Kekich, D., Sadoshima, J., Herbig, U., Tang, Q., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121499119 · Cited by 57
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“240 Correspondingly, truncal vagotomy prevents the spread of α -syn from the gut to the brain, which is associated with neurodegeneration and behavioural de fi cits.”
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“30,87 This linear hypothesis elucidates the major pathologic outcomes that arise from imbalances in homoeostasis at various scales, from the molecular to the cellular and ultimately to the organ layers, as well as the interconnections among them.”
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549 · cited 4×
“85 The hallmarks of brain ageing are broadly consistent with these hallmarks, but speci fi c characteristics have been identi fi ed, such as aberrant neural network activity and glial cell activation.”
InfluentialThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Inflamm‐aging: An Evolutionary Perspective on Immunosenescence
FRANCESCHI, C., BONAFÈ, M., VALENSIN, S., OLIVIERI, F., DE LUCA, M., OTTAVIANI, E., & DE BENEDICTIS, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06651.x · Cited by 5,358
Research works printed but not linked: 1
- Gao, Y. et al. beta2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function. Cell 186, 1026–1038 e1020 (2023). · DOI · Paper page
Cited by
Voicu, V. A., Toader, C., Șerban, M., Covache-Busuioc, R.-A., & Ciurea, A. V. (2025) · Biomedicines · doi:10.3390/biomedicines13082025 · Cited by 69
Ткаченко, Г. М., Buyun, L., Kołodziejska, R., Kamiński, P., & Kurhaluk, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188907 · Cited by 52
Li, Z., He, B., Li, Y., Liu, B.-F., Zhang, G., Liu, S., Hu, Y., & Li, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c04337 · Cited by 42
Goel, F. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01794-y · Cited by 39
HDACs in the Brain: From Chromatin Remodeling to Neurodegenerative Disease
Diniz, L. P., Pinheiro, P. D. S. M., Franco, L. S., & Gomes, F. C. A. (2025) · Cells · doi:10.3390/cells14171338 · Cited by 30
Metadata
- Authors
- Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., & Wang, Y.-J.
- Affiliations
- Army Medical University (CN)
- Chongqing Institute for Brain and Intelligence (CN)
- Chinese Academy of Sciences (CN)
- Wenzhou Medical University (CN)
- The University of Melbourne (AU)
- Corresponding author
- Masters, Colin L.
- Wang, Yan-Jiang
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-03-10
- Volume
- 10
- Issue
- 1
- Pages
- 76-76
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11891338
- OpenAlex
- W4408266534
- Cited by
- 165
- References
- 553
- Citations by year
- 2026: 100 · 2025: 65
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- neurodegenerative diseases, Alzheimer's disease, dementia, aging, cognitive decline, disease-modifying therapy, neuroprotection, vascular comorbidities, rejuvenation
- MeSH terms
- Aging, Alzheimer Disease, Brain, Humans, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. https://app.cochat.ai/papers/10.1038/s41392-025-02145-7
- The paper
- Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., & Wang, Y.-J. (2025). Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02145-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.